# EDGAR Filing Document

**Accession Number:** 0001584371
**File Stem:** 0001213900-26-034173
**Filing Date:** 2026-3
**Character Count:** 5634
**Document Hash:** bd716d8d6651719010376b653ec8a95c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-034173.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001213900-26-034173

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Good Shad
- **CENTRAL INDEX KEY:** 0002047216

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40753
- **FILM NUMBER:** 26793489

**MAIL ADDRESS:**
- **STREET 1:** C/O ICECURE MEDICAL LTD.
- **STREET 2:** 7 HA'ESHEL ST., PO BOX 3163
- **CITY:** CAESAREA
- **STATE:** L3
- **ZIP:** 3079504
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IceCure Medical Ltd.
- **CENTRAL INDEX KEY:** 0001584371
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 HA'ESHEL ST., POB 3163
- **CITY:** CAESAREA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 38900
- **BUSINESS PHONE:** 972-4-6230333

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 HA'ESHEL ST., POB 3163
- **CITY:** CAESAREA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 38900

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Good Shad<br><sub>(Last) (First) (Middle)</sub><br>7 HA'ESHEL ST., PO BOX 3163<br><sub>(Street)</sub><br>CAESAREA, ISRAEL 3079504<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>IceCure Medical Ltd. [ ICCM ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_VP, Sales for North America_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary shares | 156455<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Share option (right to buy) | <sup>(2)</sup> | 2033-08-14 | Ordinary shares | 50000 | $1.22 | D |  |
| Share option (right to buy) | <sup>(3)</sup> | 2034-07-02 | Ordinary shares | 72756 | $0.92 | D |  |

---

### Footnotes:

(1) Represents (i) 6,578 ordinary shares, (ii) 60,630 restricted stock units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of remain unvested as of March 18, 2026, (iii) 52,719 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 36,528 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.

(2) The options were granted on August 14, 2023, 25% of which vested on August 14, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 31,250 options are vested.

(3) Share option was granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 27,283 options are vested.

**Signature:** /s/ Shad Good  
**Date:** 2026-03-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**